An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses

Oncolytic viruses can activate tumor neoantigen-specific T cell responses. However, PD-L1 upregulation on tumor cells and immune cells leads to tumor resistance to this immunotherapy approach. Here, the authors develop an oncolytic virus which expresses both a PD-L1 inhibitor and GM-CSF which allows...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Guan Wang, Xi Kang, Katherine S. Chen, Tiffany Jehng, Lindsey Jones, Jie Chen, Xue F. Huang, Si-Yi Chen
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2020
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/a3a3521c2e584a13a47f5027ebb743e3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:a3a3521c2e584a13a47f5027ebb743e3
record_format	dspace
spelling	oai:doaj.org-article:a3a3521c2e584a13a47f5027ebb743e32021-12-02T16:50:00ZAn engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses10.1038/s41467-020-15229-52041-1723https://doaj.org/article/a3a3521c2e584a13a47f5027ebb743e32020-03-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-15229-5https://doaj.org/toc/2041-1723Oncolytic viruses can activate tumor neoantigen-specific T cell responses. However, PD-L1 upregulation on tumor cells and immune cells leads to tumor resistance to this immunotherapy approach. Here, the authors develop an oncolytic virus which expresses both a PD-L1 inhibitor and GM-CSF which allows an improved tumor neoantigen-specific T cell response in preclinical models.Guan WangXi KangKatherine S. ChenTiffany JehngLindsey JonesJie ChenXue F. HuangSi-Yi ChenNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Guan Wang Xi Kang Katherine S. Chen Tiffany Jehng Lindsey Jones Jie Chen Xue F. Huang Si-Yi Chen An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
description	Oncolytic viruses can activate tumor neoantigen-specific T cell responses. However, PD-L1 upregulation on tumor cells and immune cells leads to tumor resistance to this immunotherapy approach. Here, the authors develop an oncolytic virus which expresses both a PD-L1 inhibitor and GM-CSF which allows an improved tumor neoantigen-specific T cell response in preclinical models.
format	article
author	Guan Wang Xi Kang Katherine S. Chen Tiffany Jehng Lindsey Jones Jie Chen Xue F. Huang Si-Yi Chen
author_facet	Guan Wang Xi Kang Katherine S. Chen Tiffany Jehng Lindsey Jones Jie Chen Xue F. Huang Si-Yi Chen
author_sort	Guan Wang
title	An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
title_short	An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
title_full	An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
title_fullStr	An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
title_full_unstemmed	An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
title_sort	engineered oncolytic virus expressing pd-l1 inhibitors activates tumor neoantigen-specific t cell responses
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/a3a3521c2e584a13a47f5027ebb743e3
work_keys_str_mv	AT guanwang anengineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT xikang anengineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT katherineschen anengineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT tiffanyjehng anengineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT lindseyjones anengineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT jiechen anengineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT xuefhuang anengineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT siyichen anengineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT guanwang engineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT xikang engineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT katherineschen engineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT tiffanyjehng engineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT lindseyjones engineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT jiechen engineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT xuefhuang engineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses AT siyichen engineeredoncolyticvirusexpressingpdl1inhibitorsactivatestumorneoantigenspecifictcellresponses
_version_	1718383176680734720

An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses

Documents similaires